Itolizumab
Phase 3Monoclonal antibody
Itolizumab is one of 112 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 3.
3
Indications
5
Total Trials
0
Active Trials
111
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
328 competitors in Systemic Lupus Erythematosus
#DrugCompanyPhaseTrials
1Eptanemab
UCBPhase 3
Rituxan
RochePhase 3
Medrol
PfizerPhase 3
Olumiant
Eli LillyPhase 3
Stelara
Johnson & JohnsonPhase 3
Gazyva
RochePhase 3
Rayos
RRoxane Laboratories
Phase 3
Cellcept
NovartisPhase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Tylenol
KKenvue Brands
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Acute Graft Versus Host Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Itolizumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company
- BBiotech Pharmaceutical Co., Ltd.